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BACKGROUND: Genetic variation at chromosome 9p21 is a recognized 
risk factor for coronary heart disease (CHD). However, its effect on disease 
progression and subsequent events is unclear, raising questions about its 
value for stratification of residual risk.
METHODS: A variant at chromosome 9p21 (rs1333049) was tested 
for association with subsequent events during follow-up in 103 357 
Europeans with established CHD at baseline from the GENIUS-CHD 
(Genetics of Subsequent Coronary Heart Disease) Consortium (73.1% 
male, mean age 62.9 years). The primary outcome, subsequent CHD 
death or myocardial infarction (CHD death/myocardial infarction), 
occurred in 13 040 of the 93 115 participants with available outcome 
data. Effect estimates were compared with case/control risk obtained 
from the CARDIoGRAMplusC4D consortium (Coronary Artery Disease 
Genome-wide Replication and Meta-analysis [CARDIoGRAM] plus The 
Coronary Artery Disease [C4D] Genetics) including 47 222 CHD cases and 
122 264 controls free of CHD.
RESULTS: Meta-analyses revealed no significant association between 
chromosome 9p21 and the primary outcome of CHD death/myocardial 
infarction among those with established CHD at baseline (GENIUS-
CHD odds ratio, 1.02; 95% CI, 0.99–1.05). This contrasted with a 
strong association in CARDIoGRAMPlusC4D odds ratio 1.20; 95% CI, 
1.18–1.22; P for interaction <0.001 compared with the GENIUS-CHD 
estimate. Similarly, no clear associations were identified for additional 
subsequent outcomes, including all-cause death, although we found a 
modest positive association between chromosome 9p21 and subsequent 
revascularization (odds ratio, 1.07; 95% CI, 1.04–1.09).
CONCLUSIONS: In contrast to studies comparing individuals with CHD 
to disease-free controls, we found no clear association between genetic 
variation at chromosome 9p21 and risk of subsequent acute CHD events 
when all individuals had CHD at baseline. However, the association with 
subsequent revascularization may support the postulated mechanism of 
chromosome 9p21 for promoting atheroma development.
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Using a case-control approach, a large number of common genetic variants have now been associated with coronary heart disease (CHD) 
through genome-wide association studies, in an ef-
fort largely led by the CARDIoGRAMPlusC4D consor-
tium (Coronary Artery Disease Genome-wide Rep-
lication and Meta-analysis [CARDIoGRAM] plus The 
Coronary Artery Disease [C4D] Genetics).1 Among 
these variants, the chromosome 9p21 locus was the 
first to be discovered and the variant with the largest 
individual effect and is the most widely replicated ge-
netic risk factor for CHD.2–4 Multiple studies including 
case-control and prospective cohort studies in general 
populations have reliably confirmed its effect on risk 
of CHD among otherwise healthy individuals.5
However, it is uncertain whether variants at the 9p21 
locus also affect risk of recurrent or subsequent events, 
including mortality in those with established CHD. Elu-
cidation of this hypothesis would help to better under-
stand its mechanism and estimate its incremental value 
for stratification of residual risk. Prior studies have shown 
conflicting results, although most have been underpow-
ered. A literature-based meta-analysis indicated a null 
association of chromosome 9p21 variants with subse-
quent CHD events but was based on summary, not indi-
vidual level data, with varying outcome definitions.6,7
The new collaborative GENIUS-CHD (Genetics of 
Subsequent Coronary Heart Disease) consortium, 
described in this issue of the journal, was established to 
investigate genetic determinants of disease progression 
following an index CHD event.8
In this article, we use the GENIUS-CHD resource to: (1) 
examine the association of variants at the 9p21 locus on 
risk of subsequent CHD events in individuals with estab-
lished CHD; (2) compare these to the association between 
chromosome 9p21 and any CHD observed in the CARDIo-
GRAMPlusC4D consortium; and (3) explore the potential 
impact on these estimates of biases that might affect genet-
ic association studies of disease outcome and prognosis.
METHODS
In accordance with Transparency and Openness Promotion 
Guidelines, the data, analytic methods, and study materi-
als will be made available to other researchers for purposes 
of reproducing the results or replicating the procedure. 
Participating studies received local institutional review board 
approval and included patients who had provided informed 
consent at the time of enrollment. The central analysis sites 
also received waivers from their local institutional review 
board for collating and analysing summary level data from 
these individual studies. Details about the GENIUS-CHD 
consortium and study inclusion criteria have been published 
separately in this issue of the journal,8 whereas for this study 
full details about data sources, genetic variant selection, 
outcomes and statistical analyses are available in the Data 
Supplement.
RESULTS
In total, 49 studies from the GENIUS-CHD consor-
tium contributed to the federated analysis resulting 
in a sample size of 103 357 individuals of European 
descent with established CHD and available genotype 
data at the 9p21 locus. Of these, 93 115 individuals 
had available data for the primary composite outcome 
of subsequent CHD death/myocardial infarction (MI), 
of whom 13 040 experienced these events. Contrib-
uting study details are provided in Table. Participant 
characteristics are representative for populations with 
established CHD with a weighted mean age of 62.9 
years; 73.1% male. As expected, risk factor preva-
lence was high in this population, including diabetes 
mellitus (24.4%), hypertension (59.1%), and current 
smoking (25.7%). Statin use at enrollment varied by 
study, ranging from 5.2% to 97.3%, with a median 
of 61.5% (Table).
The rs1333049 single nucleotide polymorphism 
was genotyped in 42 studies, with the remaining 7 
studies using highly correlated proxies (R2>0.90); 
rs10757278 (4 studies) or rs4977574 (3 studies) when 
the primary single nucleotide polymorphism was 
unavailable. Genotyping details are provided in Table I 
in the Data Supplement. For rs1333049, the average 
risk allele frequency across the participating studies 
was 0.518 ranging from 0.453 to 0.587 (Figure I in 
the Data Supplement).
From CARDIOGRAMplusC4D, after excluding 6 
cohorts which had contributed data to both consortia, 
data were available for association with chromosome 
9p21 from 41 studies, including 47 222 cases with CHD 
and 122 264 controls free of any CHD.
Power to detect different effect sizes, including the 
effect size identified in CARDIoGRAMplusC4D, using a 
2-sided alpha of 0.05, are provided in Table II in the 
Data Supplement.
Chromosome 9p21 Association With 
Subsequent CHD Events
Study-specific results for the association between chro-
mosome 9p21 and risk of the primary outcome of CHD 
death or MI among individuals with established CHD 
at baseline, adjusted for age and sex are presented in 
Figure II in the Data Supplement.
The per-allele odds ratio (OR) for the primary out-
come during follow-up was 1.02 (95% CI, 0.99–1.05). 
The effect estimate again for the primary outcome, 
based on a time to event analysis and using a Cox 
regression model, was also similar with a hazard ratio 
of 1.02 (95% CI, 0.99–1.04; Figure III in the Data 
Supplement).
In contrast, a meta-analysis of CARDIOGRAMIplus 
C4D data (excluding studies also contributing data to 
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GENIUS-CHD), revealed a per-allele OR for a CHD event 
similar to that reported previously (OR, 1.20; 95% CI, 
1.18–1.22). There was evidence of statistical hetero-
geneity between the estimates (interaction P<0.001), 
Figure 1.
Subgroup Analyses
We found minimal evidence for heterogeneity in effect 
estimates when stratifying by CHD subtype at baseline 
(interaction P value 0.801), with no clear evidence for 
an effect of chromosome 9p21 genetic variation on 
subsequent CHD death or MI in individuals enrolled 
with acute coronary syndrome (OR, 1.02; 95% CI, 
0.97–1.06), those with coronary artery disease with 
a prior MI (OR, 1.01; 95% CI, 0.96–1.05), and those 
with coronary artery disease without prior MI (OR, 1.01; 
95% CI, 0.95–1.08, Figure 1).
We further examined the effect of chromosome 
9p21 on the primary outcome in prespecified subgroup 
analyses. We noted a borderline nominally significant 
interaction with sex, suggesting a greater risk among 
women with the chromosome 9p21 risk allele, for sub-
sequent CHD death/MI (interaction P value = 0.04), 
whereas nonsignificant trends were noted for greater 
risk in those without hypertension (P value=0.08) or 
without renal impairment (P value=0.17). There were 
minimal differences in effect estimates by other patient 
level characteristics including age and diabetes mellitus 
or according to statin or antiplatelet use or left ven-
tricular impairment at baseline (Figure IV in the Data 
Supplement).
Similarly, when stratified by study level features, 
we observed minimal evidence for heterogeneity in 
effect estimates by study size, geographic region, 
study design, or length of follow-up (Figure V in the 
Figure 2. Association between chromosome 
9p21 and secondary outcomes in partici-
pants with baseline CHD, within GENIUS-
CHD (Genetics of Subsequent Coronary 
Heart Disease).  
All meta-analysis estimates were adjusted for 
age and sex. CHD indicates coronary heart 
disease; CVD, cardiovascular disease; MI, myo-
cardial infarction; and OR, odds ratio.
Figure 1. Association between chromosome 9p21 and subsequent coronary heart disease (CHD) events in all participants with baseline CHD 
(GENIUS-CHD [Genetics of Subsequent Coronary Heart Disease]) compared with association in CHD cases and CHD-free controls (CARDIoGRAM-
PlusC4D).  
For the CARDIoGRAMPlusC4D consortium (Coronary Artery Disease Genome wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease 
[C4D] Genetics) meta-analysis estimate, 6 studies (LURIC, LIFE-Heart [The Leipzig Heart Study], GoDARTS [Genetics of Diabetes Audit and Research in Tayside Scot-
land], OHGS [Ottawa Heart Genomics Study], PROSPER [Prospective Study of Pravastatin in the Elderly at Risk], WTCCC [Welcome Trust Case Control Consortium]) 
were excluded as they were also included in GENIUS-CHD. Estimates for GENIUS-CHD are also presented by subtype of CHD at baseline, including acute coronary 
syndrome (ACS), stable coronary artery disease (CAD) without prior myocardial infarction (MI; CAD/no MI), and stable CAD with prior MI (CAD/MI). All estimates 
were adjusted for age and sex.
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Data Supplement). However, when ordered by date of 
first enrollment, there was no evidence for variation 
in effect by time of enrollment (Figure II in the Data 
Supplement).
Secondary Outcomes
We additionally examined the association between chro-
mosome 9p21 and other subsequent events available for 
this analysis within the GENIUS-CHD Consortium, listed in 
Table III in the Data Supplement, with summary estimates 
provided in Figure 2. Of note, the per-allele effect of risk 
variants at chromosome 9p21 on subsequent revascular-
ization during follow-up was 1.07 (95% CI, 1.04–1.09). 
The effect on the composite outcome of any cardiovas-
cular disease, which includes revascularization, was also 
significant at 1.04 (95% CI, 1.02–1.07). However, there 
was no clear evidence of association for the remaining 
secondary outcomes, with only a marginal trend to pro-
tection for both subsequent heart failure (OR, 0.97; 95%, 
CI 0.93–1.01) and cardiovascular disease death (OR, 0.97; 
95% CI, 0.94–1.01), as shown in Figure 2.
Selection Bias
To explore the potential for index event bias, we 
looked for differences in associations between chro-
mosome 9p21 and known cardiovascular risk factors 
in the United Kingdom Biobank, among the subset 
of participants with established CHD, compared with 
the full UKB cohort (Table IV in the Data Supplement). 
Although there were differences between the groups 
in the prevalence or values of the tested risk factors, 
we did not find clear evidence to indicate a distortion 
in associations between chromosome 9p21 and age, 
blood pressure, diabetes mellitus, or smoking. There 
was, however, a small difference for body mass index, 
with a greater statistical association between the chro-
mosome 9p21 risk allele and lower body mass index 
identified in those with established CHD than in the 
general population (nominal interaction P value 0.02, 
Table IV in the Data Supplement).
We also observed that the chromosome 9p21 risk 
allele frequency in those surviving with CHD, both in 
UKB (0.529) and in GENIUS-CHD (0.518, Figure I in the 
Data Supplement), was higher than the general popula-
tion in the UKB (0.481) and European reference popula-
tions from the 1000 Genomes (Phase 3),9 (0.472). This 
difference in frequency confirms the association of chro-
mosome 9p21 with CHD and also indicated absence 
of a crude survival bias with loss of large numbers of 
risk allele carriers to fatal events before entry into CHD 
cohorts. We did, however, observe a trend to an age 
association in those with established CHD, as well as the 
general population in the UKB, with lower chromosome 
9p21 risk allele frequencies with advancing age, relative 
to younger carriers (Figure VI in the Data Supplement).
DISCUSSION
In this study, we examined the effect of genetic varia-
tion at the chromosome 9p21 locus on risk of subse-
quent events in 103 357 individuals with established 
CHD using the newly formed GENIUS-CHD consor-
tium.8 We found that (1) in contrast to the known 
strong association with CHD observed in CARDIo-
GRAMPlusC4D, there was a markedly attenuated and 
nonsignificant association with subsequent CHD events 
in GENIUS-CHD; (2) effect estimates in GENIUS-CHD 
were broadly consistent in stratified analyses based on 
features related to study design, patient characteris-
tics, and type of index CHD event; and (3) exploratory 
analyses suggested that selection biases were unlikely 
to explain the discrepancy. However, we did find evi-
dence of an association between these variants and a 
secondary outcome of future revascularization events. 
Our findings, taken together with those from others, 
support the view that chromosome 9p21 promotes 
CHD through progressive stable atheroma rather than 
through development of an unstable phenotype.
The chromosome 9p21 locus is the most widely repli-
cated genetic risk locus for CHD identified to date, with 
an estimated 15% to 35% increased risk in carriers of 
the variant allele in prospective population and case-
control studies.5 However, studies examining the effect 
on subsequent CHD events in people with known CHD 
at baseline have reported conflicting results.10–14 Our 
group previously examined this in a literature-based 
meta-analysis, based on 15 studies with median sample 
size of 1750 individuals, accruing 25 163 cases of estab-
lished CHD, and reported no clear evidence of an effect 
of variants at chromosome 9p21 on the risk of subse-
quent events.6 An analysis by the CHARGE consortium 
(The Cohorts for Heart and Aging Research in Genomic 
Epidemiology) of 2953 MI survivors also reported no 
association with subsequent mortality.7 However, the 
limited size of most prior studies and the limitations 
of literature meta-analyses indicate that many possible 
explanations, including errors in risk allele coding and 
selection biases, could not be adequately explored, pre-
cluding meaningful interpretations for any mechanistic 
or clinical implications.
The emergence of the GENIUS-CHD Consortium has 
now permitted a robust evaluation of the role of chro-
mosome 9p21 in subsequent CHD event risk, revealing 
a clear lack of association with a common compos-
ite coronary end point. This is in marked contrast to 
findings from studies comparing cases to CHD-free 
controls, as confirmed through meta-analysis of CAR-
DIoGRAMPlusC4D data. Furthermore, we were able to 
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add to previous findings by showing that the type of 
CHD at baseline, whether acute coronary syndrome or 
stable CHD with or without prior MI, does not alter this 
association. We also interrogated several widely pro-
posed explanations that could account for our findings 
through prespecified subgroup analyses and confirmed 
that most of these, specifically older age, medication 
use at baseline (statin or antiplatelet), study size or 
follow-up duration, did not appreciably alter the asso-
ciation findings. Our finding of a possible interaction 
with sex, warrants further investigation but should be 
considered hypothesis-generating given the borderline 
evidence of an interaction.
Selection bias (ie, index event bias or collider-strat-
ification bias) could potentially explain reversed or 
attenuated associations in disease progression studies 
like this, operating by inducing relationships between 
(otherwise independent) risk factors through the selec-
tion of individuals with disease.15,16 Specifically, individ-
uals surviving a first event consequent on exposure to a 
particularly strong risk factor may have lower levels of 
exposure to other individually weaker, independent risk 
factors, which can then attenuate the association of the 
risk factor of interest with subsequent events. However, 
the distribution of common risk factors by chromosome 
9p21 genotype did not differ when compared between 
the general population and the subset with CHD in the 
UKB, using interaction tests. The only exception was for 
body mass index, a potentially differential association 
with chromosome 9p21 in those with CHD compared 
with the general population was noted. However, the 
effect size was small in both populations and on its 
own is unlikely to indicate presence of substantial index 
event bias.
Selection bias may also theoretically occur by focus-
ing on subjects surviving a first event, where chro-
mosome 9p21 risk allele carriers at risk of fatal CHD 
events are lost before enrollment into CHD cohorts, 
thereby diluting the future impact of the variant on 
subsequent CHD events. In this scenario, we would 
expect a lower risk allele frequency in those surviv-
ing CHD and entering CHD cohorts, but we found no 
evidence for this. Among those with CHD in the UKB, 
and among the whole UKB cohort, we did find a pro-
gressive loss of risk allele carriers with increasing age, 
consistent with prior findings of a greater association 
with CHD, among younger individuals in case-control 
studies.5 Given patients with CHD are generally older, 
it is possible that a subtle survival bias may still be 
influencing our findings, although all analyses were 
adjusted for age. However, based on simulation mod-
eling, sample size, and projected single nucleotide 
polymorphism effect size, we and others have previ-
ously estimated that selection biases are only minimal-
ly operating in this context and would be unlikely to 
account for our observed findings.17,18 Although our 
findings potentially argue against important selection 
biases in the analysis for the primary outcome, they 
are relatively insensitive assessments and may not fully 
elucidate such biases.
Possible biological explanations could also exist for 
our findings. Pathological studies indicate differences 
between chronic stable atherosclerotic plaques that 
cause ischemia through progressive vessel occlusion 
and vulnerable plaques with thin caps, prone to sudden 
plaque rupture, unheralded MI, and coronary deaths.19 
In a seminal study dissecting the phenotype of CHD, a 
lack of effect for chromosome 9p21 and MI was noted, 
when both cases and controls had underlying athero-
sclerosis.20 Our group and others have in parallel shown 
that chromosome 9p21 robustly associates with athero-
sclerotic phenotypes,21 whereas functional studies have 
also implicated this region with molecular activity that 
drives atheroma.22 Furthermore, in this study, we show 
that the only outcome positively associated with chro-
mosome 9p21 is incident revascularization, perhaps 
reflecting more severe atherosclerosis burden. Collec-
tively, these data support the concept that chromosome 
9p21 promotes progressive atheroma formation and 
does not confer risk via plaque rupture.
In this context, it is worth noting that chromosome 
9p21 associates more robustly with CHD in case-con-
trol studies than in prospective cohort studies.7 The 
difference, as proposed by others, could hypothetical-
ly be accounted for by incidence-prevalence bias, with 
chromosome 9p21 carriers more likely to survive a 
CHD event and thus be over represented among CHD 
cases (the opposite to survival bias described above).7 
This becomes more likely as stated above if chro-
mosome 9p21 drives a more progressive and stable 
atheroma phenotype. If this holds true, then among 
survivors with established CHD, one might expect that 
chromosome 9p21 carriers could hold a small favor-
able advantage over those who experience CHD in its 
absence, due instead to other more dangerous or vul-
nerable characteristics, and despite undergoing more 
subsequent revascularization, these chromosome 
9p21 carriers do not experience more dangerous or 
fatal events.
These findings have important implications. Clini-
cally, they indicate that a degree of caution should be 
applied when considering or evaluating patients for 
chromosome 9p21 to predict disease progression or 
residual risk. They also highlight the need to appreci-
ate important biases that may inflate or attenuate asso-
ciation findings in the setting of subsequent events for 
individuals with established disease. Mechanistically, 
these findings support existing and emerging efforts 
seeking to elucidate the mechanism of the most robust 
genetic discovery for CHD in recent decades.
There are important limitations to consider. First, 
among individuals in GENIUS with established CHD, 
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the timing of the first CHD event or age of onset was 
often unknown, so we could not account for this vari-
able in our analyses. However, the lack of association in 
the acute coronary syndrome studies, which had docu-
mented timing of the first event, suggests this did not 
impact the findings. Second, we had limited informa-
tion on whether subsequent revascularization events 
were late staged procedures, which would count as 
part of the index CHD event or unplanned and symp-
tom driven and thereby a true subsequent event, which 
may have diluted the effect estimate. Third, although 
we did not observe a specific interaction for statin or 
aspirin use, we cannot rule out an effect of combined 
or additional medication usage attenuating the asso-
ciation signal, given the high prevalence of second-
ary prevention drug use in this setting compared with 
general population cohorts. Fourth, our analyses were 
restricted to participants of European descent as most 
of the included studies only recruited these individu-
als, and so we were markedly underpowered to explore 
associations in other ethnic groups. Unfortunately, 
this remains a wider problem of genetic research and 
global efforts are ongoing to address this imbalance. 
Finally, variability of follow-up duration across studies 
is an analytical challenge and could have impacted our 
findings, through misclassification. However, a sensi-
tivity analysis stratifying on the follow-up duration of 
individual studies (<5 or 5≥ years) revealed minimal 
evidence (P=0.62) of heterogeneity in effect estimates 
(Figure V in the Data Supplement), suggesting that this 
is unlikely to have influenced our findings significantly 
as effect estimates were concordant across studies with 
different lengths of follow-up. Our major strengths, 
however, include the size of the study and the large 
number and types of subsequent events and an effort 
to examine for selection biases. We also sought to 
mitigate potential miscoding of the risk allele, given 
rs1333049 is a palindromic single nucleotide polymor-
phism, and also the risk allele C changes from being a 
minor allele in population cohorts to the major allele in 
CHD cohorts. Finally, this analysis benefitted from the 
collective expertise and input of over 170 investigators 
and analysts, many of whom have previously reported 
on chromosome 9p21.
In conclusion, using the newly formed GENIUS-CHD 
consortium, we demonstrate that variation at chro-
mosome 9p21 shows no clear association with risk 
of subsequent CHD events when all individuals have 
established CHD at baseline. This is in marked contrast 
to prior case-control studies examining odds of CHD 
presence compared with disease-free controls. We 
could not account for the attenuation of effect in terms 
of selection biases or subgroup effects. However, we 
did find a greater risk for incident revascularization in 
those with established CHD, and although residual bias 
may be at play, our findings collectively support the 
view that chromosome 9p21 promotes CHD through 
progressive stable atheroma rather than through devel-
opment of an unstable phenotype.
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